Navigation Links
NeoStem, Inc. Names Edward Geehr, M.D. to Board of Directors; Biotechnology Executive Brings Scientific and Business Experience in Global Operations

NEW YORK, Nov. 4 /PRNewswire-FirstCall/ -- NeoStem, Inc. (NYSE Amex: NBS), announced today that Edward C. Geehr, M.D. has been named to the Company's Board of Directors. Dr. Geehr brings extensive experience in developing and operating global biotechnology businesses.

Serving as Executive Vice President of Operations, Dr. Geehr was responsible for the global commercial operations of Abraxis Bioscience, a global biotechnology company dedicated to the discovery, development and delivery of next-generation therapeutics and core technologies that offer patients safer and more effective treatment for cancer and other critical illnesses.

Previously Dr. Geehr served as President of Allez Spine, LLC, a developer, manufacturer and distributor of medical devices, and was a co-founder and executive chairman of IPC-The Hospitalist Company, which became a publicly traded company in 2008. A graduate of Yale University, Dr. Geehr received his Medical Degree from Duke University. He trained in Emergency Medicine at UCLA and subsequently obtained Board certification. He is the author of many scientific articles and books and held a faculty appointment at the University of California, San Francisco School of Medicine.

Robin Smith, M.D., MBA, NeoStem's Chief Executive Officer, said, "We are extremely pleased that Dr. Geehr is joining our Board of Directors. His experience in the growing fields of molecular science and treatments for critical illnesses, combined with his leadership in developing and operating global biotechnology businesses, will expand the scientific and practical knowledge governing NeoStem's decision-making as we move into a new growth era as a result of our acquisition last week of China Biopharmaceuticals Holdings, Inc., which is anticipated to close before the end of this week."

Dr. Geehr stated, "I'm delighted to join the Board of Directors of NeoStem Inc. This is an extraordinary, dynamic company led by thoughtful executives and directors who have a strong knowledge base in science and technology as well as in commercial business development. It will be a pleasure to work with them to promote the growth of this rapidly expanding international company."

About NeoStem, Inc.

NeoStem is engaged in the business of developing stem cell therapies, pursuing anti-aging initiatives and is developing a network of adult stem cell collection centers that are focused on enabling people to donate and store their own (autologous) stem cells when they are young and healthy for their personal use in times of future medical need. The Company is also the licensor of various stem cell technologies, including a worldwide exclusive license to VSEL(TM) Technology which uses very small embryonic-like stem cells, shown to have several physical characteristics that are generally found in embryonic stem cells, and also is pursuing the licensing of other technologies for therapeutic use. For more information, please visit:

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2008 and the Company's other periodic filings with the Securities and Exchange Commission. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

                NeoStem, Inc.
                Robin Smith, Chief Executive Officer
                T: 212-584-4180

SOURCE NeoStem, Inc.

SOURCE NeoStem, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. China Biopharmaceuticals Holdings, Inc. Shareholders Overwhelmingly Support Merger with NeoStem, Inc., a NYSE AMEX Listed Company Trading Under Symbol NBS
2. AIDS Healthcare Foundation Names Homayoon Khanlou, M.D. as its Chief of Medicine, U.S.
3. Global HIV Vaccine Enterprise Names Alan Bernstein as Inaugural Executive Director, Opens New Secretariat
4. Xytis Names Gordon H. Busenbark as Chief Financial Officer
5. PLC Medical Systems Names Lead Investigators for Pivotal Trial to Evaluate RenalGuard System(TM) and RenalGuard Therapy(TM)
6. Association of Clinical Research Organizations (ACRO) Names Dr. Derek Winstanly Chair-Elect
7. California Cryobank Names Richard Jennings President of FamilyCord Division
8. Zeltiq Aesthetics Names Gordie Nye to Serve as New CEO
9. ParagonRx Names Ellen M. Derrico To Chief Marketing Executive Post
10. Boston Business Journal Names NxStage(R) Medical Third Fastest Growing Company in Massachusetts
11. NovaBay Pharmaceuticals Expands Management Team; Names Mark Anderson, Ph.D. as Chief Scientific Officer
Post Your Comments:
(Date:12/1/2015)... Dec. 1, 2015  Six months of adjunctive metformin therapy ... 1 diabetes, according to new research from T1D Exchange ... may have a beneficial effect on measures of obesity, including ... of the Journal of the American Medical Association , ... effect of metformin on overweight and obese adolescents with type ...
(Date:12/1/2015)... 1, 2015 During the recent 2015 ... San Francisco, CA , Medinol Ltd. continued ... marketplace. During a satellite symposium, "The BioNIR eDES: ... Minimize Restenosis", a renowned physician panel discussed the ... CoCr Coronary Stent System and the Medinol eDES ...
(Date:12/1/2015)... Russia has always been a country of choice for ... Europe in 2015 were tested in phase II-III ... has always been a country of choice for global multi-center phase ... in 2015 were tested in phase II-III clinical trials ... always been a country of choice for global multi-center phase III clinical ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... ... Growth in medical payments per workers’ compensation claim in Louisiana slowed from 2011 ... according to a recent study by the Workers Compensation Research Institute (WCRI). , ... per claim with more than seven days of lost time continued to be higher ...
(Date:12/1/2015)... Wayland, MA (PRWEB) , ... December 01, 2015 , ... ... adults has a tattoo — a number even greater among Millennials (a whopping one ... there are more and more people who are dissatisfied with their ink. In fact, ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... technicians must mark the film for accurate interpretation by the radiologist. The marking ... an inventor from Sacramento, Calif., has found a way to alleviate this problem. ...
(Date:12/1/2015)... ... 01, 2015 , ... Next IT Healthcare, the leader in ... this year’s Fierce Innovation Awards: Healthcare Edition, an awards program from the publisher ... in the category of Digital Solutions for its innovative, industry-leading product, Alme Health ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... Effective Post-Affiliation Integration ,” addresses a main “pain point” for merging or aligning ... results, once a deal is signed. This quick-read guidance suggests that failing ...
Breaking Medicine News(10 mins):